TC BioPharm (Holdings) PLC announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000. This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment. The Company expects to implement the improved manufacture process into its current facility in the next 24 months.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | -2.61% | -1.75% | -64.67% |
May. 15 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading | MT |
May. 15 | TC Biopharm Plc Announces Launch of Compassionate Use Program for TCB008 | CI |
1st Jan change | Capi. | |
---|---|---|
-64.67% | 3.61M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- TCBP Stock
- News TC Biopharm (Holdings) Plc
- TC BioPharm PLC Increases Treatment Capacity with Expanded Manufacturing Process